2014
DOI: 10.1016/j.antiviral.2014.08.016
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
20
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 24 publications
(20 citation statements)
references
References 44 publications
0
20
0
Order By: Relevance
“…Passive immunotherapy with Z3G1 significantly protected mice from influenza A infection via ADCC. 123,124 These results indicate that M2 may also induce protection through an ADCC-dependent mechanism. …”
Section: Universal Antibody-dependent Cell-mediated Cytotoxicitymentioning
confidence: 90%
“…Passive immunotherapy with Z3G1 significantly protected mice from influenza A infection via ADCC. 123,124 These results indicate that M2 may also induce protection through an ADCC-dependent mechanism. …”
Section: Universal Antibody-dependent Cell-mediated Cytotoxicitymentioning
confidence: 90%
“…Furthermore, Z3G1 offered protection in mice infected with different strains of influenza virus, including amantadine-and oseltamivir-resistant strains [20]. As well, Z3G1 reduced lung pathology in monkeys infected with a 2009 pH1N1 strain [20]. Another humanized monoclonal antibody with neutralizing activity against the pH1N1 influenza virus was expressed in a m ammalian cell line [21].…”
Section: Therapeutic Antibodiesmentioning
confidence: 97%
“…The treatment with Z3G1 can be administered at late as 3 days postinfection, and it still offered significant protection of mice against the lethal virus challenge. Furthermore, Z3G1 offered protection in mice infected with different strains of influenza virus, including amantadine-and oseltamivir-resistant strains [20]. As well, Z3G1 reduced lung pathology in monkeys infected with a 2009 pH1N1 strain [20].…”
Section: Therapeutic Antibodiesmentioning
confidence: 98%
See 1 more Smart Citation
“…In a recent study of antibody therapy, Song et al generated mab Z3G1 against the M2 matrix protein, which cross-reacted against M2 of a wide range of influenza A viruses (Song et al, 2014). When the investigators challenged cynomolgus macaques with an isolate of the 2009 pandemic H1N1 virus and gave them IV Z3G1 the day before or the day after infection, they observed less weight loss, a maintenance in blood oxygen saturation and less lung damage at necropsy, compared to controls; however, treatment did not prevent fever or reduce virus shedding.…”
Section: Experimental Infections Of Nhps With Human Influenza VImentioning
confidence: 99%